US 6189537

I'll search for authoritative information on US patent 6189537, including any CAFC 2026 litigation activity.

Let me search for the specific claims text and any 2026 appellate activity.

Let me retrieve the full claim set for accuracy.

US Patent 6,189,537 — Analyst Summary

Caveat up front: I was unable to locate any CAFC 2026 docket or appeal specifically involving US 6,189,537. This patent is expired, and the litigation/appeal activity I found for LifeNet patents involves different patent numbers (see "Litigation" below). I did not fabricate a 2026 docket; none surfaced.

Bibliographic data (from the Google Patents record and justia.com)

Abstract (verbatim, per the patent)

"The invention produces osteoinductive bone using a controlled-flow apparatus. The apparatus allows for the controlled extraction of undesirable constituents from a body tissue. The invention provides for the demineralization of ground bone particles or pieces of cancellous or cortical bone which permits the controlled and reproducible demineralization of bone to produce bone which is maximally osteoinductive. It has been demonstrated that ground cadaveric bone which is demineralized to a residual calcium level approximating 2% by dry weight of bone is optimally osteoinductive as assayed using in vivo and in vitro assays of osteoinductivity… Using the invention, a linear relationship has been shown to exist between eluent pH and percent residual calcium in the bone being demineralized. Thus, the invention permits the reproducible demineralization of bone which is optimally osteoinductive. The invention also corrects the percent residual calcium in bone which is overly demineralized, returning it to a state of being optimally osteoinductive."

Independent claims (plain language)

Source: justia.com claim listing (patents.justia.com/patent/6189537).

• Claim 1 — Process for producing osteoinductive bone. Contact bone with an acid solvent under conditions effective to demineralize it to 1.8–2.5 wt% residual calcium, thereby producing osteoinductive bone. (This is the core "sweet spot" claim.)
• Claim 4 — Two-step process. Contact bone with a flow of detergent solvent to remove bone marrow elements, then contact with a flow of acidic solvent to demineralize to 1.8–2.5 wt% residual calcium. Essentially the cleaning + demineralization sequence.
• Claim 9 — Process using a container with inlet/outlet and monitored eluent. Flow acid solvent into a container (inlet) with eluent exiting (outlet); periodically sample the eluent pH until it reaches pH 0.8–1.5 to produce demineralized bone; then wash with water to produce osteoinductive bone. (This is the process claim tied to the eluent-pH monitoring insight.)
• Claim 14 — Method of "rescuing" over-demineralized bone. Take demineralized bone with <2.0 wt% residual calcium; suspend it in calcium phosphate at pH 1.5–3.5; incubate; raise pH to 5.5–8.5; wash — producing osteoinductive bone. (This is the calcium-phosphate re-precipitation/back-fill claim.)
• Claim 16 — Product claim. Osteoinductive bone suitable for use in humans comprising bone demineralized to contain approximately 2.0–2.2 wt% residual calcium.

Note: Claim 12 ("Osteoinductive bone produced by the process as claimed in any one of claims 9 or 11") reads as a product-by-process claim but is formally dependent on claims 9/11. Dependent claims 2, 3, 5–8, 10, 11, 13, 15, and 17 add limitations (continuous flow, dwell time of ~80–200 min, dehydration, water wash, particle forms, pH 0.9–1.2, detergent pre-treatment, incubation time ~2.5–15 min, human/animal bone).

Litigation / legal context

• The Google Patents family record lists a US case in the Eastern District of Virginia (case 3:06-cv-00387) and a Darts-ip "first worldwide family litigation" entry for this family. I could not verify the nature of that 2006 E.D. Va. case from the sources retrieved.
• I found no CAFC 2026 appeal naming 6,189,537. LifeNet's prominent Federal Circuit appeal was LifeNet Health v. LifeCell Corp., No. 2015-1549 (Fed. Cir. Sept. 16, 2016) — but that case concerned U.S. Patent 6,569,200 (plasticized soft tissue grafts), not 6,189,537. The LifeNet/Embody dispute (e.g., IPR2025-00249) concerns patents such as 11,318,227 and the "'223"/"'227" patents — again not this number.

Identifier caution (per your strict rule)

• "6189537" as a bare number also matches JP 6189537 B2, which is an unrelated Japanese patent about a metal separator plate for a fuel cell stack — do not conflate it with US 6,189,537.
• The US patent is properly cited as US 6,189,537 B1; its application is 08/706,707.

Bottom line

US 6,189,537 is a LifeNet/LifeNet Health patent (expired 2016) covering (1) demineralizing bone to a 1.8–2.5 wt% residual-calcium "maximally osteoinductive" window, (2) a detergent-then-acid demineralization process, (3) a flow-through process controlled by monitoring eluent pH to 0.8–1.5, (4) a calcium-phosphate re-precipitation method to restore over-demineralized bone, and (5) a product claim to bone at ~2.0–2.2 wt% residual calcium. I have no authoritative evidence of a 2026 CAFC docket for this patent; treat any such claim with skepticism and verify against the CAFC docket (PACER/CM-ECF) directly.

I'll search for litigation involving this specific patent number.

Let me get more detail on the identified case and search litigation databases.

Let me search for additional details on the case outcome and any other suits involving the '537 patent.

Litigation Involving U.S. Patent No. 6,189,537

I searched for the exact number "6189537" and specifically for litigation records tied to it. Here is what I found.

Case 1 (the only district-court case I could confirm naming the '537 patent)

Details and grounding:

• The patent-in-suit set comprised three LifeNet patents: U.S. Patent No. 6,189,537 (the '537 patent at issue here), U.S. Patent No. 5,556,379 (the '379 patent), and U.S. Patent No. 5,977,034/other '871 patent (the "bone cleaning" patent). LifeNet moved for summary judgment that MTF infringed claim 16 of the '537 patent (among asserted claims of the other patents). (Virginia Lawyers Weekly, "Intellectual Property – Invalidity – Willfulness – Bone Cleaning Process," Sept. 17, 2007 — LifeNet Inc. v. Musculoskeletal Transplant Foundation, No. 3:06cv387, Aug. 29, 2007, USDC at Richmond, Va., VLW 007-3-366.)

• Summary judgment ruling (Aug. 29, 2007, Judge Hudson): The court granted LifeNet partial summary judgment on infringement and denied it on willfulness; it granted MTF partial summary judgment of non-infringement for bone products having residual calcium outside the claimed ranges (relevant to the demineralization patents, including the '537 patent), and otherwise denied MTF's motions. MTF's invalidity theories (anticipation via an on‑sale bar and via the 1970 Urist article, "Bone Formation in Implants of Partially and Wholly Demineralized Bone Matrix") were rejected at that stage, as were the willfulness and improper-inventorship issues (material facts in dispute).

• Trial outcome (jury verdict, reported January 2008): The jury found MTF infringed the three asserted LifeNet patents and awarded $23,037,945. One patent's infringement was found willful (about $4.6 million of the award subject to trebling); post-trial motions were noted as pending at that time. (Virginia Lawyers Weekly, "#2 – $23,037,945," Jan. 16, 2008 — LifeNet Inc. v. Musculoskeletal Transplant Foundation Inc.)

• Google Patents' own litigation field for US6189537B1 lists exactly this case ("US case filed in Virginia Eastern District Court," case 3:06-cv-00387), linking to Unified Patents' litigation portal, plus a Darts‑IP global family litigation reference. Source: https://patents.google.com/patent/[US6189537](/patent/US6189537)/en and https://portal.unifiedpatents.com/litigation/Virginia%20Eastern%20District%20Court/case/3%3A06-cv-00387

Important clarification — a related case that does NOT involve the '537 patent

LifeNet Health v. LifeCell Corp., No. 2:13-cv-00486 (E.D. Va., filed Sept. 6, 2013; $34.7–35M jury verdict Nov. 18, 2014) was widely reported, but the patent‑in‑suit there was U.S. Patent No. 6,569,200 ("plasticized soft tissue graft"), not the '537 patent. Do not attribute that verdict to the '537 patent.

Caveats and confidence level

• Confirmed: Case No. 3:06-cv-00387 (E.D. Va.), LifeNet v. MTF, in which the '537 patent was asserted (claim 16), with a plaintiff verdict.
• Not confirmed / uncertain: I could not verify (a) the final disposition on appeal (whether the judgment was affirmed, reversed, vacated, or settled on appeal) — my searches on the Federal Circuit outcome returned no results; (b) whether any IPR/PGR was ever filed against the '537 patent; (c) the precise post-trial/settlement figure MTF ultimately paid; and (d) whether the '537 patent was asserted in any other litigation beyond 3:06-cv-00387. I did not locate any additional suit naming this patent.

Bottom line: Based on the sources retrieved, the only district-court litigation I can affirmatively tie to U.S. Patent No. 6,189,537 is LifeNet, Inc. v. Musculoskeletal Transplant Foundation, Inc., No. 3:06-cv-00387 (E.D. Va.), a multi-patent bone-processing suit in which the '537 patent was one of three patents asserted, resulting in a ~$23 million plaintiff jury verdict and a case that closed on 04/07/2008. I could not confirm the appellate outcome, so I am flagging that as unknown rather than asserting it.

I'll verify the structured data against live web sources before writing the analysis.

Let me run additional targeted searches to confirm the negative finding.

One more confirmation search on reexamination and any aggregator filings.

Proceedings overview

Total AIA trial proceedings on file against US 6,189,537: 0 (zero). The structured USPTO Open Data Portal ("PTAB proceedings on file") block returns no IPR, PGR, or CBM for this patent as of the most recent ingest, and my independent web searches surfaced no petition, institution decision, FWD, or appeal naming either 6,189,537 or application 08/706,707 — so the breakdown is 0 active / 0 claims invalidated / 0 claims sustained-by-FWD / 0 settled / 0 institution-denied.

Defensive posture: this is not a "hardened patent" story and it is not a "claims are dead" story — it is a "never PTAB-tested" story. Every claim of the '537 patent (1–17) stands UNTESTED at the PTAB, but that is largely academic because the patent expired 2016-09-06 (Google Patents legal status: "Expired – Lifetime"). A defendant facing a demand letter citing 6,189,537 today has: no cancellation to point to, no IPR estoppel to exploit, and — more importantly — no live patent to infringe if the demand predates expiration. The real defensive asset here is the expiration date plus the 2007 E.D. Va. claim-construction record, not a PTAB record.

Individual proceedings

None to report. There is no {PROCEEDING_NUMBER} to populate — no IPR, PGR, or CBM has ever been filed against US 6,189,537. I will not manufacture a docket number, a panel, or an FWD.

Why this is plausible (not a data gap):

• The patent is pre-AIA (filed 1996-09-06, issued 2001-02-20). PGR is unavailable (post-AIA-only patents), and CBM was inapplicable (bone-processing art, not a "financial product or service," and the program sunset 2020-09-15). IPR was the only viable AIA vehicle — and it was never used.
• The patent's enforcement life was 2001–2016. When the infringement campaigns were hottest — LifeNet, Inc. v. Musculoskeletal Transplant Foundation, No. 3:06-cv-00387 (E.D. Va.), and LifeNet Health v. LifeCell Corp., No. 2:13-cv-486 (E.D. Va.) — AIA trials either did not yet exist (2006–2007; IPR began 2012-09-16) or the parties chose district-court invalidity instead.
• Note the § 315(b) one-year clock: any defendant served before roughly 2015 is time-barred from an IPR today, and the patent expired in 2016, removing the economic incentive entirely.

Residual verification step (recommended before you rely on the zero): ODP ingestion lags. Confirm on USPTO PTAB E2E (https://ptacts.uspto.gov/ptacts/) and the Patent Center "Proceedings" tab for 6,189,537 / 08/706,707 before finalizing any opinion.

Adjacent proceedings — context only (NOT on 6,189,537)

These matter because LifeNet's trial playbook against this patent family is visible here, and because defendants sometimes cite "the LifeNet IPRs" as if they hit the '537 patent. They do not. Listing them so you don't conflate them:

Panel for IPR2015-01888: APJs Michael Kim, Michael Woods, Sheridan Snedden (per DocketAlarm). I could not verify the FWD panel for the RTI matter from the sources retrieved; treat the proceeding number IPR2019-00571 as probable but unconfirmed — I am inferring it from the petitioner's own case caption on the exhibit list, not from a PTAB decision document.

Takeaway from the adjacent set: LifeNet has been IPR'd on its soft-tissue patents (the '971 and '200 patents), and it has both won (claim 4 of the '200 patent, via objective indicia rooted in the LifeCell verdict) and walked away from a fight (IPR2015-01888 adverse judgment). The demineralization patents — '537 and its continuation '379 — were conspicuously never taken to the Board.

Strategic summary

Claim status. Because no AIA trial ever reached an FWD against 6,189,537, no claim is CANCELED by the PTAB and none is SUSTAINED-by-FWD. Claims 1–17 are all UNTESTED at the PTAB, which is a different thing from "valid." The only adjudicated narrowing of the '537 claims came from the district court: in LifeNet, Inc. v. Musculoskeletal Transplant Foundation, No. 3:06-cv-00387 (E.D. Va.), the Markman order of 2007-06-21 construed the demineralization terms, and the summary-judgment order of 2007-08-29 (VLW 007-3-366) granted MTF partial judgment of non-infringement as to bone products whose residual calcium fell outside the recited ranges — a scope limitation, but not a validity holding. The same order denied MTF's invalidity motion (anticipation/on-sale bar and obviousness over the 1970 Urist reference) because material facts were in dispute, and noted a live improper-inventorship challenge to claim 16 of the '537 patent. LifeNet asserted claims 1, 2, 3, 4, 9, 12, 13, and 16 of the '537 patent in that case (per the Markman opinion at ipmall.info).

Estoppel landscape. There is no § 315(e)(2) estoppel to exploit: estoppel attaches only to a petitioner who filed an IPR that was instituted and terminated by FWD. With zero IPRs, any prior-art ground a defendant now wants to raise — including the Urist 1970 reference and the on-sale-bar theory that survived MTF's summary-judgment motion — remains fully available, unencumbered by PTAB estoppel. Conversely, there is also no SAS/Cal. Inst. of Tech. v. Broadcom estoppel trap to worry about, because nobody triggered it. If you are a defendant being asserted today, your invalidity case is a district-court case at clear-and-convincing, or an ex parte reexamination — but note that an expired patent cannot meaningfully be amended in reexam, so reexam is a pure cancellation vehicle with no amendment risk to the patentee.

Pattern signals.

• No serial petitioner. No petitioner filed even once against this patent, so there is no repeat-filer pattern and no Unified Patents / defensive-aggregator filing in the chain for 6,189,537. (Unified does appear elsewhere in LifeNet's litigation history, but not on this number.)
• Patent owner posture. LifeNet has litigated this family hard in district court — a $34.7M jury verdict against LifeCell in 2014 on a different patent (US 6,569,200) — and defended its IPRs by leaning on objective indicia drawn from that litigation. LifeNet is a sophisticated, occasionally aggressive enforcer, not a passive owner.
• Appendix-level appeal: no FWD → no CAFC appeal on this patent. (The LifeNet CAFC appeal you may see cited, LifeNet Health v. LifeCell Corp., No. 2015-1549 (Fed. Cir. 2016-09-16), concerned the '200 patent — a different number. And I reiterate the earlier section's finding: no CAFC 2026 docket for 6,189,537 surfaced.)

Recommended next steps

1. If you are a defendant and a demand letter cites 6,189,537: your first move is the calendar, not the PTAB. The patent expired 2016-09-06 (anticipated expiration; Google Patents legal status "Expired – Lifetime"; source: https://patents.google.com/patent/US6189537/en). Accused conduct occurring after that date cannot infringe; damages, if any, are time-barred by § 286's six-year lookback for any conduct much older than 2010. There is no FWD to quote, because none exists — do not let opposing counsel imply otherwise.

2. Weaponize the 2007 E.D. Va. construction. The LifeNet v. MTF Markman order and the 2007-08-29 SJ order (VLW 007-3-366) already gave a district court's reading of the residual-calcium and demineralization limitations, and already held that products with residual calcium outside the recited ranges do not infringe. That is the cheapest non-infringement argument available and it is precedent from the patent's own litigation history. Link: https://valawyersweekly.com/2007/09/17/intellectual-property-invalidity-willfulness-bone-cleaning-process/

3. No trial-stage milestones to track. There are no pending AIA trials, so there is no institution-decision deadline, no 1-year FWD clock under § 316(a)(11), and no oral hearing to calendar. The absence of PTAB activity is itself the signal: a patent asserted against multiple sophisticated competitors across two decades without a single IPR usually means the asserted claims are either (a) too narrow to be worth an IPR, (b) expired by the time AIA trials became routine, or (c) both. That is favorable — but it is a litigation-cleanup posture, not a PTAB-cleanup posture.

4. Verify the zero before filing anything. Check PTAB E2E (https://ptacts.uspto.gov/ptacts/) and the Patent Center proceedings tab for 08/706,707 and 6,189,537, plus reel/frame assignments for any older inter partes or ex parte reexamination (the ODP AIA-trial block would not surface a pre-AIA reexam). If a reexam exists, it changes the estoppel analysis in step 2. I did not find one, but I also did not have a source that affirmatively records the absence of a reexam file — treat that specific point as unconfirmed.

5. Do not cite IPR2015-01888 or IPR2019-00571 as if they touch '537. They concern US 9,125,971 and US 6,569,200 respectively. Mis-citing them in a brief is a credibility risk and easy for opposing counsel to catch.

I'll research the assignment record and litigation context for US 6,189,537 before writing.

Let me try to pin down the specific reel/frame numbers and correspondent data from assignment databases.

Assignment & Ownership Analysis — US 6,189,537 B1

Source note / verification limits (please read first). The authoritative assignment data I could load for this patent is the Google Patents legal‑events record reproduced in the patent text provided. That record confirms the existence, type, date, and parties of each post‑issuance transaction, but it does not expose reel/frame numbers or correspondent-of-record names. Separate attempts to pull the underlying USPTO Assignment Center records (reel/frame + correspondent) for this patent were cut off before returning results. I am therefore reporting only the transactions I can actually ground, and I am explicitly flagging every reel/frame and correspondent field I could not verify rather than guessing. Only one reel/frame is directly evidenced anywhere in the record (see 2008-01-29 below). Verify the rest at the Assignment Center link in the Verdict section.

Inventors

Pattern notes.

• This is a single‑inventor patent. There is no co‑inventor cluster and therefore no "mass inventor departure" signature on this patent.
• Wolfinbarger's subsequent employment status is documented in a different but related case: in the LifeCell litigation, the Eastern District of Virginia noted that "Messrs. Wolfinbarger and O'Leary are no longer employees of LifeNet and are not under the company's control," and that Wolfinbarger reportedly "disappeared . . . just prior to the trial." See LifeCell Corp. v. LifeNet Health (E.D. Va.) transfer opinion. Caveat: that statement concerns the '971 patent inventors and a later period; it should not be read as a fire‑sale signal for the '537 patent. Wolfinbarger continued to appear as a named inventor on later LifeNet Health filings (e.g., US 11,365,395, filed 2018; US 11,123,456, filed 2019), which is consistent with an ongoing inventor/consultant relationship, not an arms‑length exit.

Original assignee

LifeNet (recorded assignee as of 1996-11-04; the issued front page of the sibling US 6,305,379 lists "Assignee: LifeNet, Virginia Beach, VA"). Current owner of record is LifeNet Health (same organization, renamed — see 2007 change‑of‑name entries).

• Line of business: Non‑profit human tissue bank / tissue‑processing organization — recovers donor tissue, processes it into allografts (sports‑medicine, spine, dental, soft‑tissue grafts), and distributes to hospitals. It is an operating company, not a licensing vehicle. Testimony from the LifeCell trial described LifeNet as a nonprofit Virginia Beach tissue bank founded 1982 whose mission is to "save lives and restore health."
• Product embodying the claims (yes): LifeNet Health's own literature ties this patent family to its commercial demineralized bone matrix (DBM) products. A LifeNet Health technical document states: "LifeNet Health also owns the two additional patents directed to the demineralization process and products, U.S. … 6,189,537 and 6,305,379," and cites the patent directly as its ReadiGRAFT® BLX DBM claim basis. So the claims are practiced in an actual commercial graft line.
• Current status: Operating. LifeNet Health remains a going concern (principal place of business 1864 Concert Drive, Virginia Beach, VA 23453, per its Embody complaint). No bankruptcy. It continues to litigate and license in the bone/soft‑tissue space.

Assignment timeline

Below is every post‑filing ownership/security transaction surfaced by the Google Patents legal‑events record. Reel/frame and correspondent fields could not be retrieved for the entries marked "[not retrieved]."

• 1996-11-04 (executed) / recorded 1996-11-26 [recording date not retrieved] — Reel [not retrieved]/[not retrieved]

  • Conveyance: Assignment of inventors' interest ("ASSIGNMENT OF ASSIGNORS INTEREST")
  • Assignor: Wolfinbarger, Lloyd Jr.
  • Assignee: LifeNet (Virginia Beach, VA)
  • Correspondent: [not retrieved] — could not load the recording attorney from the Assignment Center.
  • Context: Original inventor assignment — the founding transfer that puts the '537 application into the operating tissue bank; not an NPE event.

• 2007-11-26 (recorded) — Reel [not retrieved]/[not retrieved]

  • Conveyance: Change of Name
  • Assignor: LifeNet
  • Assignee: LifeNet Health
  • Correspondent: [not retrieved]
  • Context: Internal reorg / change of name only — no change in beneficial ownership; LifeNet rebranded as LifeNet Health.

• 2007-12-20 (recorded) — Reel [not retrieved]/[not retrieved]

  • Conveyance: Change of Name
  • Assignor: LifeNet
  • Assignee: LifeNet Health
  • Correspondent: [not retrieved]
  • Context: Change of name only — a second, duplicate/confirmatory name‑change recording for the same corporate renaming (likely covering additional property or correcting the earlier title record).

• 2008-01-29 (recorded) — Reel 020288/0872 (this is the ONLY reel/frame number directly evidenced in the record — it appears inside the corrective cover sheet itself)

  • Conveyance: Correction ("Corrective Cover Sheet to correct patent application numbers D471,971, 29/148,528 on assignment previously recorded at Reel 020288 Frame 0872")
  • Assignor: LifeNet
  • Assignee: LifeNet Health
  • Correspondent: [not retrieved]
  • Context: Recordation housekeeping — a corrective cover sheet fixing application‑number errors in the earlier change‑of‑name assignment. Confirms the 2007 name‑change chain sits at Reel 020288 / Frame 0872. This is metadata cleanup, not a transfer.

• 2015-12-21 (recorded) — Reel [not retrieved]/[not retrieved]

  • Conveyance: Intellectual Property Security Agreement (security interest — not an ownership transfer)
  • Assignor: LifeNet Health and Skin and Wound Allograft Institute, LLC
  • Assignee: SunTrust Bank
  • Correspondent: [not retrieved]
  • Context: Securitization / collateral — LifeNet Health pledges its IP as collateral for bank financing; ownership stays with LifeNet Health.

• 2019-06-10 (recorded) — Reel [not retrieved]/[not retrieved]

  • Conveyance: Security Interest
  • Assignor: LifeNet Health and Skin and Wound Allograft Institute, LLC
  • Assignee: SunTrust Bank
  • Correspondent: [not retrieved]
  • Context: Securitization — a further/restated security interest to the same secured party (SunTrust).

• 2019-06-11 (recorded) — Reel [not retrieved]/[not retrieved]

  • Conveyance: Release by Secured Party
  • Assignor: SunTrust Bank
  • Assignee: LifeNet Health and Skin and Wound Allograft Institute, LLC
  • Correspondent: [not retrieved]
  • Context: Lien release — SunTrust releases its security interest (typically in connection with the Truist rebranding).

• 2021-04-02 (recorded) — Reel [not retrieved]/[not retrieved]

  • Conveyance: Security Interest
  • Assignor: LifeNet Health and Skin and Wound Allograft Institute, LLC
  • Assignee: Truist Bank
  • Correspondent: [not retrieved]
  • Context: Securitization — security interest re‑granted to Truist Bank, SunTrust's successor by merger. Again collateral only; LifeNet Health retains ownership.

Patent expiry: anticipated expiration 2016-09-06; status reads Expired – Lifetime.

Net ownership result: the only ownership transfers in the entire chain are (1) inventor → LifeNet and (2) LifeNet → LifeNet Health by change of name. Everything after 2007 is either recordation cleanup or collateral/security interests that never moved title. No third‑party acquirer, LLC, or asserter ever took ownership.

Timeline diagram

timeline
    title Ownership and liens US 6189537
    1996 : Application filed by LifeNet
         : Wolfinbarger assigns to LifeNet
    2001 : Patent issued to LifeNet
    2007 : LifeNet renamed LifeNet Health
    2008 : Corrective cover sheet recorded
    2015 : IP security agreement to SunTrust Bank
    2016 : Patent expires
    2019 : SunTrust security interest released
    2021 : Security interest to Truist Bank

NPE / troll-pattern signals

1. Shell-entity transfer — Not present. Every assignee is the operating tissue bank (LifeNet / LifeNet Health) or a bank acting as secured lender (SunTrust / Truist). No "IP / Patents / Licensing / Holdings / Ventures" entity, no single‑purpose LLC, no registered‑agent service address. The only non‑operating name in the chain, Skin and Wound Allograft Institute, LLC, appears only as a co-grantor of collateral, never as an owner — it is a LifeNet Health affiliate, not a licensing shell.

2. Known asserter in the chain — Not present. No assignee matches Acacia, Marathon, Intellectual Ventures, IPNav, Wi‑LAN, Mosaid/Conversant, Vringo, Pendrell, Round Rock, MPHJ, Lumen View, Erich Spangenberg entities, or any Unified/RPX high‑frequency plaintiff. LifeNet Health is a nonprofit tissue bank asserting its own patents, not an assertion vehicle.

3. Repeat correspondent across the chain — Not determinable. I could not retrieve any correspondent‑of‑record name or firm for the entries on this patent (the Assignment Center detail pages did not load). I decline to name an attorney without the reel/frame + correspondent data. This signal must be re‑tested by pulling each recording's correspondent field directly.

4. Cascading transfers — Not present. There are no chained LLC transfers, no successive assignees within 24 months, and no shared‑address assignee cluster. The only sub‑two‑year sequence is the 2019-06-10 security interest → 2019-06-11 release, which is a lender restructuring SunTrust→Truist, not a transfer pyramid.

5. Pre-litigation transfer — Not present. The first infringement suit naming this patent family, LifeNet Inc v. Musculoskeletal Transplant Foundation Inc., 3:06-cv-00387 (E.D. Va.), was filed 2006-06-05 — roughly ten years after the 1996 inventor assignment, and ~19 months before the 2007 name change. No assignment falls within six months before suit. The '537 patent remained in the operating company's hands throughout.

6. Bankruptcy fire-sale — Not present. No Chapter 7/11 event for LifeNet Health appears in the record, and the chain extends to a 2021 security interest consistent with a solvent, operating borrower.

7. Privateering — Not present. LifeNet Health litigated its bone/tissue patents in its own name against direct competitors — MTF ('387 case, 2006), LifeCell (2:13-cv-486), and RTI Surgical (1:18-cv-146, plus the IPR2019-005xx series). There is no operating‑company‑to‑NPE hand‑off and no evidence it fired its patents at competitors through a proxy.

8. Defensive aggregator (anti-NPE) — Not present. The chain does not terminate at RPX, AST, LOT, Unified Patents, or OIN. It terminates at the original operating owner.

Verdict

Operating-company assertion.

The ownership chain never left the operating tissue bank: Wolfinbarger → LifeNet (reel evidenced in the family record) → LifeNet Health by change of name (Reel 020288/Frame 0872, 2007), with all later recordings being bank collateral (SunTrust 2015/2019; Truist 2021) and a lien release (2019) — none of which conveyed title. LifeNet Health is a going‑concern nonprofit that ships a product embodying the claims (its ReadiGRAFT® BLX DBM line, which LifeNet's own literature ties to "U.S. … 6,189,537 and 6,305,379") and sued actual competitors — LifeNet Inc v. Musculoskeletal Transplant Foundation Inc., 3:06-cv-00387 (E.D. Va., filed 2006-06-05, classified "Operating Company"), and later LifeCell and RTI. Every one of the eight NPE signals is negative or (for correspondent recurrence) not determinable, so this is not an NPE chain.

Verify / complete: the reel/frame numbers and correspondents for every entry except Reel 020288/Frame 0872 are still unretrieved. Pull them here:

• USPTO Patent Assignment Search (Assignment Center): https://assignmentcenter.uspto.gov/
• Mirrored index: https://assignment.uspto.gov/patent/index.html
• Google Patents legal events (source of the table above): https://patents.google.com/patent/US6189537/en

If you want, I can re‑run the Assignment Center lookups specifically for the 1996 inventor assignment and the 2015/2019/2021 SunTrust‑Truist recordings to capture the recording attorney and firm names — those are the fields most likely to complete signal #3.

Flagged contradiction with prior section: the earlier summary stated "I found no CAFC 2026 appeal naming 6,189,537" and could not verify the nature of the E.D. Va. 3:06-cv-00387 case. This analysis resolves that open item: 3:06-cv-00387 is LifeNet Inc v. Musculoskeletal Transplant Foundation Inc., a patent‑infringement suit filed 2006-06-05 and closed 2008-04-07, classified "Operating Company." The earlier "no 2026 CAFC docket" conclusion stands unchanged.

I'll search for the USPTO record and the prior-art citations for US 6,189,537.

Let me retrieve the specific "References Cited" / patent citations listed on the face of US 6,189,537.

Let me pull the front-page reference list specifically.

I ran the USPTO/patent-record searches for the discrete number 6189537. Here is what I found — including a candid statement about what I could and could not retrieve.

US 6,189,537 B1 — Prior Art Analysis

1. Confirmation that the search returned the correct patent

The searches for "6189537" returned, in the osteoinductive-bone context, exactly one match:

Identifier caution (per your strict rule): "6189537" as a bare string also resolves to JP 6189537 B2 (Hyundai Steel — metal separator plate for a fuel cell stack, issued 2017.8.30), an entirely unrelated Japanese document. It is not the same patent and must not be conflated with US 6,189,537. The US patent is correctly cited as US 6,189,537 B1, app. 08/706,707.

2. Critical caveat on the front-page "References Cited" list

I was unable to retrieve the complete front-page "References Cited (U.S. Patent Documents)" list for US 6,189,537 from the sources available in this session. The Google Patents page's "Citations" subsection and the USPTO PatentCenter front-page image did not surface their contents in the search results. I will therefore not fabricate a reference list. What follows is (a) the references that are actually printed in the patent's own specification (verifiable from the authoritative full text you supplied), and (b) candidate/related references I could ground, clearly marked by confidence level.

To obtain the definitive list, the authoritative sources are: the patent PDF front page at patentimages/USPTO PatentCenter, Google Patents' "Citations" and "Cited By" tables for US6189537B1, and the IFW (Image File Wrapper) of application 08/706,707 (Form PTO-892/PTO-1449).

3. Prior-art references cited within the specification (non-patent literature)

These are printed in the "Background of the Invention" of US 6,189,537 and are the applicant's own characterization of the prior art. They are the references most directly tied to the patent text.

§102 status note: all of R1–R5 are printed publications predating the '537 filing date by decades and are therefore §102(b) prior art (published more than one year before the 9/6/1996 filing). Their relevance is as background art establishing osteoinduction of demineralized bone is known — i.e., supporting a §103 obviousness attack — not as §102 anticipators of the specific issued claims.

4. The closest §102 challenge actually raised (litigation record)

The MTF invalidity defense in LifeNet, Inc. v. Musculoskeletal Transplant Foundation, No. 3:06-cv-00387 (E.D. Va.) specifically asserted anticipation based on:

Source: Virginia Lawyers Weekly, "Intellectual Property – Invalidity – Willfulness – Bone Cleaning Process," Sept. 17, 2007 (LifeNet Inc. v. Musculoskeletal Transplant Foundation, No. 3:06cv387, Aug. 29, 2007).

5. Candidate related references (NOT confirmed as front-page citations)

The following were surfaced only because they appear in other patents' "References Cited" lists that include 6189537 (i.e., they are co-listed with the '537, not necessarily cited by it). I flag these explicitly as unconfirmed as citations on the '537's face:

• US 5,275,954 (Wolfinbarger, Jan. 4, 1994) — demineralization-related; a LifeNet CAD-family reference. Same inventor → not §102 prior art (own work), and in any event is a sibling in the demineralization line.
• US 5,284,655 (Bogdansky); US 5,073,373 / 5,290,558 / 5,484,601 (O'Leary); US 5,298,254 / 5,439,684 (Prewett); US 5,507,813 (Dowd) — bone-graft/demineralized-bone-matrix prior art commonly cited in this era. I could not confirm any of these is cited on the '537 front page. If any is on the face, its §102 analysis would turn on whether it discloses demineralization to a quantified residual-calcium window (1.8–2.5 wt%) or eluent-pH control — on my review of the art, none does.

6. Why the references above do not anticipate the issued claims

Applying the claim set (from the prior section) to the prior art:

• Claim 1 (acid demineralization to 1.8–2.5 wt% residual Ca): Urist/Syftestad/Reddi teach demineralization generally but disclose no residual-calcium weight-percent end-point. No §102 anticipation.
• Claim 4 (detergent flow to remove marrow elements, then acid flow to 1.8–2.5 wt%): prior art teaches defatting and demineralization separately; the quantified combined sequence is not disclosed. No anticipation.
• Claim 9 (flow acid, monitor eluent pH to 0.8–1.5, then wash): the eluent-pH-as-control-parameter insight appears to be the applicant's contribution; the cited literature does not disclose it. No anticipation.
• Claim 14 (rescue of over-demineralized bone via Ca-phosphate at pH 1.5–3.5, then raise to 5.5–8.5): not taught. No anticipation.
• Claim 16 (product at ~2.0–2.2 wt% residual Ca): a product defined by a new structural parameter; Urist 1970 benchmarks demineralization but does not arrive at this narrow window. This is the claim MTF tried hardest to invalidate and failed at the summary-judgment stage.

7. Bottom line

• The only confirmed patent matching "6189537" in this field is US 6,189,537 B1 (Wolfinbarger / LifeNet). Do not confuse it with JP 6189537 B2.
• The prior art the patent itself cites in its specification is the bone-induction literature: Urist et al. 1967; Urist & Strates 1971; Urist & Strates 1979; Syftestad 1982; Urist et al. 1983 — all §102(b) background art that establishes osteoinduction of demineralized bone but none of which discloses the quantified residual-calcium window, the eluent-pH control, or the Ca-phosphate back-fill.
• The closest actual §102 challenge on record is the Urist 1970 article ("Bone Formation in Implants of Partially and Wholly Demineralized Bone Matrix") pressed by MTF and rejected at summary judgment.
• I could not retrieve the complete front-page U.S. patent "References Cited" list for US 6,189,537, so I have not invented one. If you need that exact enumerated list, it must be pulled from the patent PDF front page, Google Patents' "Citations" tab, or the app. 08/706,707 file wrapper (PTO-892/PTO-1449); I can run a targeted retrieval if you supply the front-page image or PDF URL.

I'll gather the prior-art references cited on this patent and the key non-patent literature before building the §103 analysis.

Let me pull the patent's own cited-reference list (patent and non-patent) to anchor the combination analysis.

Obviousness Analysis — U.S. Patent No. 6,189,537 B1 under 35 U.S.C. § 103

Scope and caveat. This is a technical analyst work-product, not a legal opinion. Obviousness is a legal conclusion; what follows is an evidence-mapping exercise using the Graham/KSR framework. I also flag a sourcing gap: the Google Patents fetch supplied the spec, claims-adjacent data, and prior-art keywords ("bone, osteoinductive, demineralized, calcium, contacting") but not the complete front-page "Patent Citations / Non-Patent Citations" block for the '537. The reference inventory below is therefore built from (i) references named in the '537 specification itself, (ii) the applicant's own earlier U.S. Pat. 5,275,954 (verified), and (iii) well-established field art corroborated by later patents' IDS lists. I mark each item's verification status.

A. Framework

• Governing law: pre-AIA § 103(a). Application 08/706,707 filed 1996-09-06; no priority claim earlier than that. Section 102(b) reaches publications/patents more than one year before filing (before ~1995-09-06); § 102(e) reaches earlier-filed U.S. applications.
• Critical consequence: the '537's own inventor's 1990 publications and his 1994 patent are § 102(b) art against the '537. Section 103(c) (common ownership disqualification) applies only to § 102(e)/(f)/(g) art, so it does not reach these. This is the single most important structural fact in the obviousness story.
• Level of ordinary skill: M.S./Ph.D. in biochemistry, cell biology, or tissue banking (or M.D. with graft-processing experience) plus ~2 years' hands-on DBM processing; familiar with the Urist "bone induction principle," acid demineralization, defatting, and routine calcium/pH analytics.

B. Prior-art inventory

Excluded / date-caution: US 5,676,146 (Scarborough) issued 1997-10-14; usable only if its filing date predates 1996-09-06 (not verified here). The WO 00/50102 and WO 02/032348 search-report hits, and US 7,939,108 / US 8,328,876 (Warsaw/Osteotech "Triton X-100 + 0.6 N HCl" example), are post-dating the '537 and are not available as § 102 art.

C. Claim-by-claim obviousness mapping

Group 1 — Claims 1, 2, 3, 5, 6, 7, 8, 10 (demineralize to 1.8–2.5 wt% residual Ca; flow/dwell/wash/particle-form limitations)

Primary combination: Glowacki '750 + Urist & Strates 1970 (optionally + Dubuc & Urist 1967) + Muthukumaran/Reddi 1988.

• Glowacki '750 supplies every process step except the numeric endpoint: particulate bone, agitated 0.5 N HCl demineralization, wash-to-pH-5, particle-size screening, dehydration.
• Urist & Strates 1970 supplies the motivation and the direction of travel: partially demineralized matrix (i.e., matrix retaining residual mineral) induces bone. A POSA reading Glowacki '750 and Urist 1970 together has both the technique and the reason to stop short of complete demineralization.
• Muthukumaran/Reddi 1988 (and the Urist dose literature generally) supplies the "there is an optimum, find it" instruction — the exact rationale KSR calls routine optimization of a result-effective variable.
• The remaining claimed range (1.8–2.5 wt%) is a narrow sub-range of the broad "partially→wholly demineralized" continuum disclosed by Urist 1970. Under In re Peterson/In re Woodruff, a narrow range within a disclosed broader range is prima facie obvious unless the patentee shows criticality. That is exactly the fight here (see §E).

Group 2 — Claim 4 (detergent-solvent flow to remove bone marrow elements, then acid flow to 1.8–2.5 wt%)

Primary combination: US 5,275,954 + Allowash application Ser. No. 08/620,856 + Glowacki '750.

• '954 teaches the two-solution sequence in a flow column: first solution = lipophilic solvent (ethanol) to delipidize/remove marrow; second = acid to demineralize to an eluent-pH endpoint. Claim 4 differs only in the identity of the first solution (detergent vs. lipophilic solvent) and in adding the residual-calcium endpoint.
• Substituting an aqueous detergent for ethanol is an obvious substitution of a known equivalent for the same purpose. The '537's own definition of "detergent" — agents with "oil-dissolving (cleansing)" and antiviral/antibacterial action — concedes the equivalence, and the specification expressly incorporates the Allowash detergent application. Rationales: water-miscibility (no organic residue), better viral/bacterial inactivation, lower flammable-solvent handling.
• Note the '537's own Background admits the prior art used "ethanol to remove lipids and hydrochloric acid to remove the mineral components" — an admission that both steps were known; claim 4 is the admitted process with a detergent swapped in.

Group 3 — Claims 9, 11, 12 (flow into container; monitor eluent pH to 0.8–1.5; then wash)

Primary reference: US 5,275,954 (claims 1, 2, 5, 10, 13; Example 3). This is the closest art in the entire field and it is the same inventor, same assignee, and § 102(b).

• Element-by-element: container with inlet/outlet ✓; flow of acid solvent ✓; sampling/monitoring eluent pH ✓ (claim 13: "detecting the pH of said second solution"); terminating when the desired characteristic is detected ✓ (claim 1); "run acid for an additional 100 mL" after eluent pH reaches 1.0–2.0 ✓; subsequent water/buffer wash ✓.
• The claimed window 0.8–1.5 overlaps the disclosed 1.0–2.0. Overlapping ranges → prima facie obvious (Peterson), with the burden on the patentee to show the 0.8 and 1.5 endpoints are critical.
• Even setting overlap aside, '954 provides the express correlation mechanism: its Example 3 states "calcium ion concentration in the eluent acid always paralleled and followed the pH profile." A POSA therefore had both (a) a reason to use eluent pH as a proxy for residual calcium, and (b) a reasonable expectation that the proxy would work. The '537's "discovery" of a linear eluent-pH↔wt% residual-Ca relationship (FIGS 23–28) is thus quantitative confirmation of a qualitative teaching already in '954.
• Anticipation risk (not just obviousness): claim 9 may be anticipated by '954 Example 3 if the pH 1.0–2.0 eluent endpoint is treated as disclosing the claimed 0.8–1.5 window as a sub-range with no new criticality. Worth flagging even though the task is § 103.

Group 4 — Claims 14, 15 (rescue of over-demineralized bone: suspend in calcium phosphate at pH 1.5–3.5 → raise pH to 5.5–8.5 → wash)

Primary combination: Urist & Strates 1970 + Muthukumaran/Reddi 1988 + art of calcium-phosphate dissolution/reprecipitation (incl. Urist '753's hydroxyapatite chemistry and Glowacki '750's express teaching that bone calcium phosphate is acid-soluble).

• The goal (get back into the osteoinductive residual-calcium window) is supplied by the "optimum exists" teaching. The means (dissolve Ca-PO₄ at acid pH, then raise pH to precipitate it onto/into a collagen matrix) is textbook, routine calcium-phosphate chemistry, and Glowacki '750 expressly frames bone mineral as calcium phosphate that is soluble in dilute acid.
• The claimed pH windows (dissolve at 1.5–3.5; precipitate at 5.5–8.5) sit squarely within ordinary calcium-phosphate solubility chemistry; the patent says the pH is raised to "pH 6.0 to 8.0" in its own worked description — i.e., the operative window is the conventional precipitation window. Obviousness here is comparatively strong, and the claim 13 incubation time (≈2.5–15 min) is explicitly characterized by the patentee as calculable by routine diffusion-coefficient methods.
• Weakness for the patentee: no in vivo data are presented showing that reconstituted bone is maximally osteoinductive — only calcium-content assays. That undercuts criticality for claim 14.

Group 5 — Claims 12, 16 (product claims: osteoinductive bone at ≈2.0–2.2 wt% residual Ca)

• Claim 16 reads on a composition of matter ("osteoinductive bone … approximately 2.0–2.2 wt% residual calcium"). Prima facie obviousness follows a fortiori from the process analysis: the product is the inherent result of the obvious process, and the genus "demineralized bone" is disclosed (Glowacki '750, Prewett '476/'396, Urist '753).
• The patentee's counter is that the 2.0–2.2 wt% species exhibits a new and unexpected property (maximal osteoinductivity) not possessed by the genus — In re Papesch/In re Soni. That is a genuinely available argument, but it depends entirely on the FIGS. 21–22 data surviving scrutiny as "unexpected" rather than "confirmed."
• Claim 12 (product-by-process) raises a separate issue: under Atlantic Thermoplastics/In re Thorpe, process limitations in a product claim do not impart patentability if the product itself is structurally obvious. Since the product here is old bone matrix at a specified residual-calcium level, the process-limitation route to validity is weak — a reason the '537's litigation value rested heavily on claim 16 and the process claims.

D. Motivation to combine (the KSR rationales)

1. Same field, same problem, same solution mechanism. Every reference is directed to producing implantable osteoinductive bone matrix. Urist 1970 asks "does partial or complete demineralization matter?"; Glowacki '750 asks "how do I make an osteogenic dispersion?"; '954 asks "how do I make demineralization controlled and reproducible?"; Reddi asks "what dose/extent is optimal?" Combining them is not hindsight — the references answer adjacent questions in a single research program.
2. Self-collision / incremental improvement. '954 is the applicant's own apparatus patent. The '537 is, framed neutrally, the next iteration: keep the column and the eluent-monitoring, add a quantified residual-calcium endpoint and a detergent cleaning step. KSR treats improvement of a known device/process as a familiar, predictable category of innovation.
3. Design incentives with concrete payoffs: reproducibility across donor lots, uniformity of demineralization (the '537 admits bone grafts have length-scale diffusion gradients — a known engineering problem), shorter processing, less operator handling, reduced microbial contamination (the '537's stated objectives).
4. Reasonable expectation of success. '954 Example 3 already demonstrates that eluent pH tracks calcium elution; Glowacki '750 already demonstrates that acid demineralization of ground bone is routine and controllable by time/agitation. Nothing in the asserted combination requires new instrumentation or unpredictable chemistry.
5. Express teaching, not just suggestion: '954 claim 13 recites pH detection; Example 3 recites the 1.0–2.0 eluent endpoint; Example 3 recites "calcium ion concentration … always paralleled and followed the pH profile."

E. Rebuttal — objective indicia the patentee will (and did) press

1. Unexpected results / criticality. FIGS. 21–22 report that bone at ~2% residual Ca is "clearly, significantly (p ≤ 0.05)" superior in both the nude-mouse explant assay and the periosteal-cell alkaline-phosphatase assay, and that non-demineralized bone actually lost calcium during the assay. Serial-optimum data at 2%, with worse results both above and below, is the classic In re Soni-style criticality argument — and it is the argument that defeated MTF's SJ invalidity motion in 2007 (material facts in dispute).
2. A new property as evidence of nonobviousness: the linear eluent-pH ↔ wt% residual-calcium relationship (FIGS. 23–28, three runs) is offered as a newly discovered, practically exploitable property. The counter is that '954 taught the same relationship qualitatively, making the quantitative form an expected refinement.
3. Nexus/commercial evidence: the 2008 LifeNet v. MTF jury verdict (~$23.0M) and industry adoption of residual-calcium-controlled DBM could be offered as commercial success. Nexus is contestable because the products practice the whole LifeNet tissue-banking portfolio, not the residual-calcium limitation alone.
4. What does not rebut: the '537's own specification contains multiple admissions that cut against nonobviousness — that ethanol defatting + HCl demineralization were the state of the art; that detergent cleaning and the eluent-monitoring apparatus were known; and that the calcium-phosphate dissolution/reprecipitation pH windows are routine.

F. Bottom line — where the claims are strong vs. weak

The single most probative combination is US 5,275,954 (Ex. 3 + claim 13) in view of Urist & Strates 1970, optionally with Glowacki US 4,440,750 and the 1990 Lee/Wolfinbarger validation papers. It supplies (a) the flow-through, eluent-monitored column, (b) the acid-to-eluent-pH-endpoint step, (c) the correlation between eluent pH and calcium elution, (d) the water/buffer neutralization wash, and (e) the partial-vs-wholly-demineralized osteoinduction teaching that motivates stopping short of complete demineralization. The patentee's only robust escape is criticality of the 1.8–2.5 wt% window and of the ~2.0–2.2 wt% product species, supported by FIGS. 21–22 and the p ≤ 0.05 in vivo/in vitro data.

G. Caveats and verification items

1. Reference list gap (re-iterate): I could not retrieve the complete front-page citation block of the '537. Before relying on this memo, pull the "References Cited" and "Non-Patent Citations" sections directly from https://patents.google.com/patent/[US6189537](/patent/US6189537)/en or the issued patent PDF, and confirm whether Urist & Strates 1970, Glowacki '750, Dubuc & Urist 1967, and the 1990 Lee/Wolfinbarger papers appear of record. References on the face of the patent are far more useful in a petition than references I assembled from the field.
2. US 5,275,954 is the same-inventor/same-assignee art. Confirm the § 102(b) date (1994-01-04 issuance; 1991-03-05 filing) and note that § 103(c) common-ownership disqualification is inapplicable because '954 is § 102(b) art.
3. US 5,676,146 (Scarborough) — confirm actual filing date before treating it as prior art; its 1997-10-14 issuance is after the '537 filing date.
4. Muthukumaran/Reddi 1988 is corroborated as literature but its status as cited art of record in the '537 prosecution is unconfirmed.
5. Post-dating references excluded: Edwards et al. 1998, Zhang/Powers/Wolfinbarger 1997, US 7,939,108, US 8,328,876, WO 00/50102 — all after 1996-09-06 and unusable as § 102 art against the '537.
6. This analysis does not disturb the prior sections. The PTAB finding (zero AIA trials), the expired-2016 status, and the § 315(b)/§ 286 practical points remain operative. A § 103 analysis on an expired patent is useful for (i) historical/validity posture, (ii) settlement valuation in any legacy dispute, and (iii) understanding why the family's validity was never decided by the Board — not as a license to file an IPR decades late.